When should antiretroviral therapy for HIV be started?

被引：57

作者：

Phillips, Andrew N. ^{[1
]}

Gazzard, Brian G.

Clumeck, Nathan

Losso, Marcelo H.

Lundgren, Jens D.

机构：

[1] UCL Royal Free & Univ Coll Med Sch, Dept Primary Care & Populat Sci, London NW3 2PF, England

[2] Chelsea & Westminster Hosp, London, England

[3] Hosp St Pierre, Dept Infect Dis, Brussels, Belgium

[4] Hosp JM Ramos Mejia, Serv Inmunocomprometidos, Buenos Aires, DF, Argentina

[5] Hvidovre Univ Hosp, Copenhagen HIV Programme, Copenhagen, Denmark

来源：

BRITISH MEDICAL JOURNAL | 2007年 / 334卷 / 7584期

关键词：

D O I：

10.1136/bmj.39064.406389.94

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：76 / 78

页数：3

共 24 条

[1] Regional changes over time in initial virologic response rates to combination antiretroviral therapy across Europe [J].

Bannister, Wendy P. ;

Kirk, Ole ;

Gatell, Jose M. ;

Knysz, Brygida ;

Viard, Jean-Paul ;

Mens, Helene ;

Monforte, Antonella D'Arminio ;

Phillips, Andrew N. ;

Mocroft, Amanda ;

Lundgren, Jens D. .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2006, 42 (02) :229-237

[2]

Beral V, 2004, AIDS, V18, P51, DOI [10.1097/01.aids.0000096908.73209.5d, 10.1097/00002030-200401020-00006]

[3]

Blackham J, 2005, AIDS, V19, P487

[4]

BURMAN W, 2006, 16 INT AIDS C

[5] The case for conservative management of early HIV disease [J].

Burman, WJ ;

Reves, RR ;

Cohn, DL .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (01) :93-95

[6] A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome [J].

Carr, A ;

Miller, J ;

Law, M ;

Cooper, DA .

AIDS, 2000, 14 (03) :F25-F32

[7] Lipodystrophy associated with an HIV-protease inhibitor [J].

Carr, A ;

Cooper, DA .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (18) :1296-1296

[8] Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy:: a collaborative analysis of prospective studies [J].

Egger, M ;

May, M ;

Chêne, G ;

Phillips, AN ;

Ledergerber, B ;

Dabis, F ;

Costagliola, D ;

Monforte, AD ;

de Wolf, F ;

Reiss, P ;

Lundgren, JD ;

Justice, AC ;

Staszewski, S ;

Leport, C ;

Hogg, RS ;

Sabin, CA ;

Gill, MJ ;

Salzberger, B ;

Sterne, JAC .

LANCET, 2002, 360 (9327) :119-129

[9]

El-Sadr WM, 2006, NEW ENGL J MED, V355, P2283, DOI 10.1056/NEJMoa062360

[10] Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study [J].

Fellay, J ;

Boubaker, K ;

Ledergerber, B ;

Bernasconi, E ;

Furrer, H ;

Battegay, M ;

Hirschel, B ;

Vernazza, P ;

Francioli, P ;

Greub, G ;

Flepp, M ;

Telenti, A .

LANCET, 2001, 358 (9290) :1322-1327

← 1 2 3 →